| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/17/2023 | 92.8% | Alliance Global Partners | → $22.75 | Initiates Coverage On | → Buy |
| 02/09/2021 | 120.34% | HC Wainwright & Co. | $13 → $26 | Maintains | Buy |
| 05/28/2020 | 10.17% | HC Wainwright & Co. | $11 → $13 | Reiterates | → Buy |
| 04/03/2020 | -6.78% | HC Wainwright & Co. | $7 → $11 | Reiterates | → Buy |
| 12/18/2018 | -40.68% | HC Wainwright & Co. | → $7 | Initiates Coverage On | → Buy |
What is the target price for CollPlant Biotechnologies (CLGN)?
The latest price target for CollPlant Biotechnologies (NASDAQ: CLGN) was reported by Alliance Global Partners on February 17, 2023. The analyst firm set a price target for $22.75 expecting CLGN to rise to within 12 months (a possible 92.80% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for CollPlant Biotechnologies (CLGN)?
The latest analyst rating for CollPlant Biotechnologies (NASDAQ: CLGN) was provided by Alliance Global Partners, and CollPlant Biotechnologies initiated their buy rating.
When is the next analyst rating going to be posted or updated for CollPlant Biotechnologies (CLGN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CollPlant Biotechnologies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CollPlant Biotechnologies was filed on February 17, 2023 so you should expect the next rating to be made available sometime around February 17, 2024.
Is the Analyst Rating CollPlant Biotechnologies (CLGN) correct?
While ratings are subjective and will change, the latest CollPlant Biotechnologies (CLGN) rating was a initiated with a price target of $0.00 to $22.75. The current price CollPlant Biotechnologies (CLGN) is trading at is $11.80, which is within the analyst's predicted range.